Quanterix, a digital immunoassay developer backed by BioMerieux and Stratec, has raised $64.1m in its initial public offering.
Quanterix Corporation, a US-based biomarker analysis technology developer backed by medical diagnostics equipment producers BioMerieux and Stratec Biomedical, will raise $64.1m when it floats on the Nasdaq Global Market today.
The company priced the initial public offering at $15, in the middle of its $14 to $16 range, but increased the number of shares from 3.34 million to almost 4.28 million. The IPO values Quanterix at approximately $318m.
Founded in 2007, Quanterix is working on a digital immunoassay product…
